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Acellular vaccines against diphtheria-tetanus-pertussis (acellular pertussis) (DTaP) are being progressively
introduced into vaccination programs worldwide, with the aim of reducing T-helper 1 (Th1)-associated reac-
togenicity associated with the cellular diphtheria-tetanus-pertussis (whole-cell pertussis) (DTwP) vaccine. The
DTaP vaccine has an improved safety profile in infants, but little information is available concerning the
nature of the ensuing immunological memory in older children and how this may affect the reactogenicity of
DTaP booster doses. We have addressed this question in the present study by assessing polyclonal and vaccine
antigen-specific humoral and cellular immune responses to boosting with DTaP in 4- to 6-year-old children
primed during infancy with DTaP (n  30) or DTwP (n  16) and by correlating these parameters, in
particular cytokine responses, with expression of local side effects at the injection site. Large local reactions
(>50-mm diameter) 24 to 72 h after receiving the DTaP booster occurred in 43% of exclusively DTaP-primed
children, in contrast to 6% of children primed with DTwP. These reactions were associated with vigorous T
helper 2 (Th2)-polarized memory responses to vaccine antigen exemplified by interleukin 5 (IL-5), IL-6, and
IL-13 production and log-scale boosting of tetanus-specific immunoglobulin E and occurred most frequently
among children who are intrinsically “high Th2 responders” as detected by in vitro responsiveness to poly-
clonal mitogen. Our findings suggest that priming during infancy with DTaP promotes stable, boostable
Th2-polarized immunity against vaccine antigens, which in a significant subset of children is subsequently
associated with local reactions at the booster site. The time course of these reactions suggests that the
underlying mechanism involves reactivation of Th2-polarized cellular immune memory.
Morbidity and mortality to infectious diseases are maximal
during early infancy, and as a consequence, the pressure to
develop an increasingly broad range of vaccines in progres-
sively younger age groups is increasing. An archetypal example
is the diphtheria-tetanus-pertussis (DTP) vaccine, which pro-
vides protection against pathogens responsible for severe ill-
ness and death in millions of children worldwide, and initia-
tives to introduce versions of this and other vaccines for use in
neonates to provide protection during the crucial first months
of life are well advanced in many centers (3, 11, 17, 29).
The primary consideration underpinning research and devel-
opment in this area continues to be that of safety, and the first
major shift in formulation of the DTP vaccine from the original
combination of whole-cell pertussis combined with tetanus and
diphtheria toxoids (DTwP) to the new-generation acellular ver-
sion (DTaP) was driven precisely by this imperative. Notably, the
occurrence of febrile reactions in a small proportion of DTwP-
vaccinated children (6, 8, 13) which are likely to be associated with
cell-mediated responses to the vaccine has provided the impetus
for development of the second-generation DTaP, and large-scale
international trials have demonstrated efficacy with a significantly
improved safety profile with this vaccine in infants (7, 16). How-
ever, more recent studies in older children suggest that the DTaP
booster dose given at the end of the preschool years, given alone
or in combination with inactivated polio vaccine, is relatively fre-
quently associated with local side effects of redness and swelling at
the injection site (2, 14, 19, 26). The mechanism(s) underlying
these local reactions is incompletely understood and has been
variously suggested to result from the large amount of diphtheria
toxoid in the vaccine (27) or a combination of vaccine antigen-
specific immunoglobulin E (IgE) antibody (20, 24) and T helper
2 (Th2) cytokine production (24). The present study provided us
with the opportunity to directly compare local side effects to the
preschool DTaP booster with humoral and cellular immune re-
sponse profiles of individual children to vaccine antigens, con-
trasting subjects who were primed in infancy with either DTaP
vaccine or the original DTwP vaccine. Our results suggest a pos-
sible association between injection site reactions to the DTaP
booster and Th2-polarized memory against vaccine antigens
which was selectively primed in infancy by the DTaP vaccine.
MATERIALS AND METHODS
Subjects. The study complied with guidelines set by the National Health and
Medical Research Council of Australia and was approved by our institutional
human ethics committee. The study cohort consisted of 46 healthy children
between 4 and 6 years of age (median age, 54 months; age range, 48 to 74
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months). They were recruited from one of the centers (Perth) involved in an
Australia-wide randomized multicenter phase IIIb clinical trial designed to com-
pare the immunogenicity and reactogenicity of the combined Infanrix-IPV (in-
activated poliomyelitis virus) vaccine given in one arm, with Infanrix and IPV
given in separate arms. All children additionally received the measles-mumps-
rubella (MMR) vaccine. At the end of the study, examination of the infant
vaccination history of the study subjects revealed unforeseen heterogeneity with
respect to DTP priming. Notably, while all 46 of the subjects had received four
DTP vaccinations at 2, 4, 6, and 18 months, 30 were found to have received
exclusively (acellular) DTaP, whereas the priming schedules of 16 in the group
included one or more injections of the (whole-cell) DTwP. This information was
employed to stratify the population for subsequent analyses, as detailed below.
As part of the multicenter study protocol, an initial questionnaire was em-
ployed to collect demographic characteristics, such as age, gender, vaccination
history, doctor diagnosis of asthma, hay fever, eczema, or food allergy, as well as
atopic family history. Additionally, the incidence of local reactions at the site of
the DTaP booster dose (pain, redness, and swelling) were recorded during the
first 4 days postvaccination, together with any general (fever, irritability, and
drowsiness) symptoms. Using this information, the individuals were grouped on
the basis of the incidence of local reactions at the DTaP injection site. In the
analyses shown below, the children primed exclusively with DTaP were divided
into two subgroups of similar size: DTaP-reactive (DTaP-R), defined as the
children with large local reactions comprising redness with a diameter of 50
mm, and DTaP-nonreactive (DTaP-NR) designating those with smaller or no
reactions. The selection of a 50-mm cutoff defining large reactions was based on
findings from a previous publication (28). In the DTwP group who had been
given the whole-cell vaccine during infant priming, only 1 of 16 experienced a
large local reaction upon preschool boosting.
Peripheral blood was collected prior to (prebleed) and 4 to 6 weeks after
vaccination (postbooster), either into an equal volume of RPMI 1640 (Cytosys-
tems) containing preservative-free heparin or separately for serum preparation.
Peripheral blood mononuclear cells (PBMC) were isolated from diluted blood
and cryopreserved for later batch analysis, employing methodology that has been
successfully utilized in a variety of prospective cohort study settings (9, 18,
21–23).
Vaccines. Both DTaP (Infanrix; GlaxoSmithKline [GSK] Biologicals; injected
into the left deltoid) and DTaP-IPV (Infanrix-IPV; GSK Biologicals; left deltoid)
contained 25 limes flocculation doses (Lf) of diphtheria toxoid, 10 Lf of tetanus
toxoid (TT), 25 g of pertussis toxoid, 25 g of filamentous hemagglutinin, and
8 g of pertactin adsorbed on 0.5 mg of aluminum salts, and both DTaP-IPV and
IPV (IPOL; Aventis Pasteur MSD’s IPV; injected subcutaneously into the lower
right deltoid), contained 40 D-antigen (D-Ag) units of poliovirus type 1, 8 D-Ag
units of poliovirus type 2, and 32 D-Ag units of poliovirus type 3.
In addition, all children in this study were vaccinated with the MMR vaccine
(PRIORIX; GSK Biologicals; injected subcutaneously into the upper right del-
toid), which contained 103.0 50% tissue culture infectious doses (TCID50) of
Schwarz measles strain, 103.7 TCID50 of RIT 4385 mumps strain, and 103.0
TCID50 of RA 27/3 rubella strain.
Antibody assays. For the purpose of this study, the TT antigen component was
selected as representative of the DTaP vaccine, and associations are reported
below between aspects of TT-specific immunity and the most frequent local
reaction (redness) at the injection site.
TT-specific IgG was assayed as previously described (23a) with a reading of
greater than 0.1 IU/ml being considered protective.
Total IgE, IgE specific for both TT (RC 208) and house dust mite (Dermato-
phagoides pteronyssinus), Phadiatope test, and FX5 (food mix containing egg
white, cow’s milk, cod fish, wheat flour, peanut, and soya bean) were assayed via
the Pharmacia UniCAP 100 system per the manufacturer’s instructions.
Cell culture. As described elsewhere (23), cryobanked PBMC were cultured on a
batch analysis basis over a short time period, using the same reagents throughout,
with pre- and postvaccination samples from each individual being processed to-
gether. PBMC were resuspended at 1  106 cells/ml in either RPMI 1640 (Cyto-
systems) supplemented with 5% pooled human AB serum (for cultures with vaccine
antigens) or AIM-V serum-free medium (Gibco Life Technologies) supplemented
with 2-mercaptoethanol (4  105 M final concentration; Sigma) for cultures with
phytohemagglutinin (PHA). Aliquots of 0.5 106 cells were cultured for 96 h alone
or together with TT to measure responses to the DTaP vaccine (0.5 Lf/ml; CSL) or
with measles lysate (ML) or control rhesus monkey kidney cell lysate (1 in 240
dilution; generous gift from S. Wesselingh, Macfarlane Burnet Institute for Medical
Research and Public Health) to measure responses to the MMR vaccine or for 48 h
alone or together with PHA (1 g/ml; Murex Biotech).
Detection of cytokine protein. The levels of interleukin 5 (IL-5), IL-6, IL-10,
IL-13, and gamma interferon (IFN-) in PBMC culture supernatants were mea-
sured by in-house time-resolved fluorometry assays as described previously (21).
Statistical analysis. The Kruskall-Wallis test was used to compare the differ-
ences between vaccine-specific antibody and cytokine responses between the
three symptomatology groups. Where significant differences were seen, the
Mann-Whitney U test was used to do pairwise testing between the three groups.
Wilcoxon matched-pair signed-rank test was used for analysis between re-
sponses pre- versus postvaccination for each individual. Spearman’s  test was
used to analyze the correlations between the size of local reactions and cytokine
responses, and the chi-square test was used to assess differences between the
incidence of large local reactions and IgE boosting in DTaP-primed children
given different versions of IPV. Stepwise logistic regression modeling was used to
further examine associations between reactivity at the booster site and immuno-
logical indices. The statistical package SPSS (SPSS, Inc., Chicago, Ill.) was used
for all analyses.
RESULTS
The local reactions to the DTaP booster in the 46 4- to
6-year-old children reported in this study are illustrated in
Table 1. Laboratory assays (detailed below) were conducted in
a blind manner as to the clinical outcome. Of the 16 children
who had been given the DTwP vaccine during infant priming,
only 1 individual experienced a large local reaction to the
booster. In contrast, 13 of the 30 who were primed exclusively
with DTaP developed large reddening (erythema) reactions at
the injection site (DTaP  DTwP group; P  0.009), and
among this reactive subgroup the reddening was highly corre-
lated with swelling (P  0.001; 0.774 by Spearman’s ).
For subsequent analyses, the DTaP-primed group was strat-
ified into “reactors” (DTaP-R; n 	 13) versus “nonreactors”
(DTaP-NR; n 	 17), and these children were compared sep-
arately with the DTwP-primed children. TT-specific IgE and
IgG titers did not differ significantly in prebleed serum samples
from these subgroups (Fig. 1). TT-specific IgG titers boosted
equivalently in all three subgroups. However, the exclusively
DTaP-primed children with large local reactions (DTaP-R)
also displayed markedly (in some cases, log-scale) elevated
TT-specific IgE responses postboosting (Fig. 1) which were
essentially restricted to this subgroup.
Analysis of TT-specific T-cell responses in the groups re-
vealed a pattern of Th2-polarized vaccine-specific cytokine
responses, which is consistent with the TT-specific IgE anti-
body data. Notably, the DTaP-R group displayed relatively
elevated TT-specific IL-5, IL-6, and IL-13 responses at the
time of boosting (Fig. 2), which in the case of the IL-5 com-
ponent was further amplified by the booster and remained
relatively elevated thereafter (P 	 0.025; not shown).
Table 2 illustrates Spearman correlations between TT-spe-
cific humoral and cellular immune responses and the size of
TABLE 1. Summary of local reactions to the DTaP booster in the
46 children
Group (n)
% of group with the following local reaction
(diameter [mm]):
Redness Swelling
50 20–49 3–19 2 50 20–49 3–19 2
DTwP (16) 6 13 0 81 0 0 6 94
DTaP exclusively (30) 43 7 0 50 30 7 3 60
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local reactions to the booster among exclusively DTaP-primed
children. Strong associations are apparent with TT-specific
Th2 cytokine responses involving IL-5, IL-6, and IL-13 and a
weaker association with IFN-. It is additionally noteworthy
that production levels of the Th2 cytokines IL-5 and IL-13 in
response to the polyclonal T-cell mitogen PHA also correlated
with reaction size, suggesting that susceptible children are part
of a subgroup who are intrinsically high Th2 responders. This
did not in turn associate with atopy expression (data not
shown), although the sample numbers may be insufficient to
detect such relationships, particularly at this early age when
allergic manifestations are often of low intensity. In this regard,
11 of the 19 DTaP-primed children had a doctor diagnosis of
atopy or asthma, and the reaction frequency was not different
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FIG. 1. Anti-TT IgG and IgE in DTaP-R-, DTaP-NR-, and DTwP-primed groups. Serum samples taken from 4- to 6-year-old children at the time
of (prebleed) and 4 weeks after (postbooster) vaccination with DTaP were assayed for TT-specific IgG (in 103 units per liter [kU/L]) and IgE (IU/ml).
The children have been classified as DTaP-primed reactive (DTaP-R) (those with a50-mm-diameter redness at the site of the vaccine), DTaP-primed
nonreactive (DTaP-NR) (those with smaller or no reaction), and DTwP-primed (DTwP). Data are expressed as scatter plots, with the solid line
representing the median value. Below each graph, P values are shown, which were determined by the Wilcoxon matched-pair signed-rank test.
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FIG. 2. TT-specific cytokine production by PBMC. PBMC isolated from children at the time of (prebleed) vaccination with DTaP were cultured
for 96 h alone or together with TT (0.5 Lf/ml). Supernatant levels of IL-5, IL-6, IL-10, IL-13, and IFN- were determined by time-resolved
fluorometry, and IL-5, IL-6 and IL-13 data are shown here as picograms per milliliter. The change in values (treatment control) for each individual
was calculated, and the pooled data were then expressed as box plots for DTaP-R-, DTaP-NR-, and DTwP-primed groups described in the legend
to Fig. 1. The limits of the boxes represent the 25th and 75th percentiles of the results, the black line in the box represents the median (50th
percentile), and the whiskers represent the 5th and 95th percentiles. Significant differences between each of the groups are shown and were
determined by the Mann-Whitney U test for unpaired responses.
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between those with and without this diagnosis (P 	 0.183 by
chi-square test).
The degree to which DTaP-induced boosting of vaccine-
specific Th2 immunity influenced systemic Th2 immunity to
other antigens was separately analyzed. We did not detect
statistically significant differences between groups (or between
bleeds) in titers of total or house dust mite-specific IgE or in
titers of IgE to mixtures of inhalant (Phadiatope test) or food
allergens (FX5 test). Moreover, cytokine responses to the mea-
sles component of the MMR vaccine given at the time of the
DTaP boosting was comparable in all groups (data not shown).
As noted in Table 2, the polyclonal IL-5 and IL-13 response
capacity measured at the time of DTaP boosting also corre-
lated with the magnitude of the red reaction at the site of the
DTaP booster dose within the exclusively DTaP-primed group.
Stratification of this group prior to analysis revealed enhanced
overall Th2 competence, as evidenced by elevated polyclonal
IL-5 and IL-13 reactivity in the DTaP-R subgroup manifesting
the strongest local reactions (DTaP-R  DTaP-NR; P 	 0.008
for IL-5 and P 	 0.001 for IL-13; data not shown).
Stepwise logistic regression was used to further examine
associations between reactivity at the booster site (as a binary
variable, reactivity defined as redness 50 mm) and immuno-
logical indices at the prebleed (cellular immune responses and
antibody titers), adjusting for infant vaccination status and IPV
vaccination status at the time of the booster as potential con-
founding factors. As shown in Table 3, the magnitude of the Th
memory response to tetanus antigen exemplified by IL-6 pro-
duction and exclusive priming in infancy with DTaP are posi-
tively associated with reactivity to the booster. In contrast,
covaccination with IPV admixed with the DTaP booster was
negatively associated with reactivity. It is of interest to note in
this context that anti-TT IgG levels were boosted to a signifi-
cantly higher degree in children receiving the combined DTaP-
IPV relative to those given the vaccines in opposite arms
(13.7
 2.3 versus 7.6 
 1.2 IU/ml; P 	 0.031), and moreover,
a significantly lower proportion of this subgroup (3/16 children
versus 9/14 children; P 	 0.011) displayed 4-fold rise in
TT-specific IgE titers following the booster.
DISCUSSION
As detailed above, the results presented here stem from a
post hoc analysis of immunological data collected on a group
of local 4- to 6-year-old children participating in a multicenter
trial on the reactogenicity of DTaP-IPV vaccine. The analysis
was prompted by the unexpected observation of an apparently
strong association between the intensity of injection site reac-
tions postboosting and the type of DTP vaccine given earlier to
the children during infancy. Notably, large reactions were es-
sentially restricted to children primed with the acellular ver-
sion of the DTP vaccine.
While this is a small study with insufficient statistical power
to permit firm conclusions to be drawn, there are nevertheless
sufficient internal consistencies within the data set and with the
published literature, outlined below, to suggest that the obser-
vations reported merit systematic follow-up in other (and
larger) study populations.
Firstly, the overall results of this study are consistent with a
series of previous reports (2, 14, 19, 26) indicating relatively
frequent local reactions to the preschool booster in children
primed in infancy exclusively with the DTaP vaccine. More-
over, the findings are consistent with earlier reports suggesting
that the preschool DTaP booster selectively increases levels of
Th2-associated responsiveness to vaccine antigen, including
both humoral (specific IgE antibody) and cellular immunity
(24), and also with data suggesting that susceptibility to the
Th2-trophic effects of DTaP is highest among children who are
intrinsically “high Th2 responders” (4). The salient new finding
from this study is the apparent association between preexisting
Th2-polarized cellular immune memory to DTaP vaccine an-
tigen prior to administration of the preschool booster and the
subsequent expression of local reactions at the injection site
over the 24 to 72 h following administration of the booster. The
time course of these reactions reflects a delayed type as op-
posed to immediate response and is hence consistent with a
cellular (as opposed to humoral) immune etiology. Consistent
with this thesis, there was no association detected between
local reactions to the DTaP booster and circulating vaccine-
specific IgE antibody which was universally low prior to boost-
ing, although production of this antibody was triggered by the
booster.
The apparent association between Th memory and injection
site reactions suggests that susceptibility to local side effects of
the DTaP booster in preschoolers is programmed earlier dur-
ing the initial priming process in infancy. In this regard, we (22,
TABLE 2. Correlations between immune response and local reaction size
Statistic
Cellular or humoral response
IL-5 IL-6 IL-10 IL-13 IFN-
TT IgE TT IgG
TT PHA TT PHA TT PHA TT PHA TT PHA
Spearman’s  0.496 0.566 0.588 0.148 0.222 0.062 0.464 0.690 0.405 0.065 0.240 0.036
P 0.005 0.003 0.001 0.480 0.239 0.767 0.010 0.001 0.026 0.758 0.201 0.812
TABLE 3. Relationship between large local reactions (50 mm) at
preschool booster vaccination site and immune response variables
in children determined at the time of boostinga
Variable Oddsratios 95% CI
b P value
DTaP exclusively in infancy 21.926 1.682–285.871 0.018
Combined DTaP-IPV 0.136 0.022–0.858 0.034
Prebleed TT-specific IL-6 27.676 2.204–347.530 0.010
a Relationship determined by logistic regression modelling.
b 95% CI, 95% confidence interval.
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23) and others (4, 25) have previously demonstrated that T-cell
memory responses in infants to the DTaP vaccine are initially
highly Th2 polarized relative to those observed with the more
Th1-trophic DTwP vaccine, presumably reflecting a combina-
tion of the intrinsic (developmental) Th2 bias of the immature
human immune system (1, 5, 10) and the relative paucity of
Th1-stimulatory cell wall-derived microbial “danger” signals in
the DTaP vaccine (12). It appears from these and other studies
(24) that rechallenge with DTaP vaccine antigens 2 to 3 years
after priming recalls immune responses with a comparable Th2
bias, leading to the further amplification of this component of
the immune response, including stimulation of vaccine-specific
IgE production. It should be stressed that these DTaP-induced
Th2 recall responses do not spill over significantly into the
systemic compartment, as there is no evidence from this or
previous studies (24) that the preschool booster (or the earlier
priming doses of DTaP) promote environmental allergen-spe-
cific IgE antibody production.
The significance of these findings in relation to the respon-
siveness of DTaP-vaccinated children to subsequent encoun-
ters with antigens within the DTaP mixture cannot be gauged
with certainty, and it is for this reason that we believe follow-up
studies in preschool children and older age groups should be
undertaken. For example, it is a matter of potential concern
that a significant subset of exclusively DTaP-vaccinated chil-
dren exhibited marked increases in Th2-polarized vaccine-spe-
cific immunity exemplified by TT-specific IgE levels following
the DTaP booster. While the overall sample size of DTaP-
primed children is admittedly small (n 	 30), the increase in
specific IgE occurred in 60% of these subjects, but more im-
portantly, this increase was seen in 12 of the 13 children in the
subgroup manifesting large local reactions. The time frame
over which vaccine-specific Th2 immunity remains elevated
postboosting, conceivably during which the risk for further
(potentially more-intense) Th2-mediated responses to expo-
sure to vaccine antigens is high, is currently unknown and
merits more-detailed investigation of larger study populations.
In this context, components of the DTaP vaccine, such as TT,
are increasingly being used as carrier proteins to enhance an-
tibody responses to polysaccharide conjugate vaccines, such as
meningococcal C conjugate vaccines which are being adminis-
tered to preschool and school-age children as part of mass
immunization campaigns in a number of countries. If the Th2
component of memory induced by the DTaP booster proves to
be persistent in a subset of these children, this may have un-
foreseen effects on the carrier functions of DTaP-associated
proteins and hence on the efficacy and/or reactogenicity of the
vaccines in which they are used.
An additional issue which merits further investigation involves
potential interactions between the DTaP and IPV vaccines at the
booster site. In particular, it is possible that analogous to the early
phase of Th memory development in the mouse (15), Th2-polar-
ized DTaP-specific memory in 4- to 6-year-old children resulting
from infant priming may remain at least partially “plastic” and
thus susceptible to immune deviation via exposure to Th1-trophic
stimuli. This possibility was indirectly tested via the analyses in
Table 3. All the children in this study had been primed during
infancy with live (oral) polio vaccine, which promotes develop-
ment of T-cell memory comprising low-level IFN- production in
the absence of IL-5 or IL-13, indicative of overall Th1 polariza-
tion (30). The findings in Table 3 and accompanying data on titers
of TT-specific antibody demonstrate that if the DTaP booster is
accompanied by concomitant IPV boosting at the same site, en-
suing Th2-associated local reactions and the accompanying boost-
ing of TT-specific IgE are significantly reduced, while IgG boost-
ing improves. This suggests the possibility that reactivation of
Th1-polarized poliovirus-specific memory cells by IPV may pro-
vide “bystander” feedback inhibition of the Th2 component of
DTaP-specific memory, both locally and in the draining lymph
node. This possibility merits more-detailed investigation employ-
ing larger study groups, including subjects primed during infancy
with IPV, which is now used in many countries in preference to
oral poliovirus vaccine. It should additionally be noted that all the
children in this study also received the MMR vaccine, but as this
was common to all groups, it is unlikely to have contributed to the
observed effects.
In conclusion, the results of this small study point to the
possible existence of a series of underlying complexities relat-
ing to the performance of the DTaP vaccine in young children,
which become evident only when underlying DTaP-primed
memory is systematically analyzed. Several of the relevant is-
sues raised here can be partially addressed by retrospective
analysis of existing reactogenicity data from preschool booster
studies, combined with analyses in cryobanked sera of TT-
specific IgE antibody. However, our results also add further
weight to growing arguments which stress the necessity for
parallel monitoring of cellular immune indices in assessment of
the safety and efficacy of infant vaccines, as opposed to the
current practice of almost complete reliance upon markers of
humoral immunity.
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